Boehringer's Pradaxa price higher than forecast

Germany's Boehringer Ingelheim priced its new stroke prevention pill Pradaxa at $6.75 a day, higher than the $6 some analysts had expected. Report

Suggested Articles

Zantac
Manufacturing

Valisure: FDA should recall Zantac, other ranitidine antacids

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

by Eric Palmer
abbvie
Pharma

Senators urge FTC to put microscope on pharma megamergers

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

by Eric Sagonowsky
Erleada
Pharma

J&J's Erleada nabs new FDA nod in metastatic prostate cancer

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

by Kyle Blankenship